HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design-Reference-Cited by-同舟云学术

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design

Published:2014-01-03 Issue:2 Volume:6 Page:392-402
ISSN:1942-0870
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

de Goeij Bart ECG,Peipp Matthias,de Haij Simone,van den Brink Edward N,Kellner Christian,Riedl Thilo,de Jong Rob,Vink Tom,Strumane Kristin,Bleeker Wim K,Parren Paul WHI

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

http://www.tandfonline.com/doi/pdf/10.4161/mabs.27705

Reference47 articles.

1. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

2. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells

3. Specificity within the EGF family/ErbB receptor family signaling network

4. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3

5. Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bispecific antibody drug conjugates: Making 1+1>2;Acta Pharmaceutica Sinica B;2024-05

2. Next-Generation HER2-Targeted Antibody–Drug Conjugates in Breast Cancer;Cancers;2024-02-16

3. Better safe than sorry: dual targeting antibodies for cancer immunotherapy;Biological Chemistry;2024-02-01

4. Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies;mAbs;2023-11-27

5. Evaluation of ⁸⁹Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET;ACS Omega;2023-05-04